CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

40352

ADMINISTRATIVE DOCUMENTS

REVIEW OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

ANDA Number: **40-352** Dates of Submission: **December 23, 1998, January 27 and March 22, 1999**

Applicant's Name: **Mallinckrodt Inc.**

Established Name: **Meperidine Hydrochloride Tablets USP, 50 mg and 100 mg**

Labeling Deficiencies:

1. CONTAINER 100s (50 mg and 100 mg)

   Satisfactory, in draft.

2. INSERT (submitted 3/22/99)

   a. DESCRIPTION

      i. First sentence - Meperidine hydrochloride, a narcotic analgesic, is ethyl ...

      ii. Each MEPERIDINE ... tablet, for oral administration, contains:

      iii. May delete in listing of inactive ingredients.

   b. CONTRAINDICATIONS

      Second paragraph, third sentence - "reactions" (plural).

   c. WARNINGS

      Usage in Pregnancy and Lactation - Delete the second and third paragraphs.

   d. ADVERSE REACTIONS

      Add the following as the last subsection:

      Other. Antidiuretic effect.

   e. OVERDOSAGE

      Last paragraph, second sentence - Delete the last

f. DOSAGE AND ADMINISTRATION

i. For relief of Pain, first sentence - ... than with parenteral ...

ii. Last sentence - "... action of meperidine."

g. HOW SUPPLIED

i. Store at controlled ... (Delete the second "at".)

ii. Add the statement "Dispense in a tight, light-resistant container as defined in the USP."

Please revise your insert labeling, as instructed above, and submit final print container labels and insert labeling.

Please note that we reserve the right to request further changes in your labels and/or labeling based upon changes in the approved labeling of the listed drug or upon further review of the application prior to approval.

To facilitate review of your next submission, and in accordance with 21 CFR 314.94(a)(8)(iv), please provide a side-by-side comparison of your proposed labeling with your last submission with all differences annotated and explained.

/s/

Robert L. West, M.S., R.Ph.
Director
Division of Labeling and Program Support
Office of Generic Drugs
Center for Drug Evaluation and Research

BIOEQUIVALENCY COMMENTS TO BE PROVIDED TO THE APPLICANT

ANDA: 40-352 APPLICANT: Mallinckrodt Inc.

DRUG PRODUCT: Meperidine Hydrochloride Tablets, 100 mg

The Division of Bioequivalence has completed its review and has no further questions at this time. The dissolution testing will need to be incorporated into your stability and quality control programs as specified in USP 23.

Please note that the bioequivalency comments provided in this communication are preliminary. These comments are subject to revision after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling, or other scientific or regulatory issues. Please be advised that these reviews may result in the need for additional bioequivalency information and/or studies, or may result in a conclusion that the proposed formulation is not approvable.

Sincerely yours,

/S/

Dale P. Conner, Pharm. D.
Director
Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research